Target General Information
Target ID T94306
Target Name Integrin alpha-5/beta-1
Target Type Clinical Trial
Gene Name ITGA5
Biochemical Class Integrin
UniProt ID ITA5_HUMAN||ITB1_HUMAN
Target Gene Expression Profiles in the Disease-Relevant Drug Targeted Tissue of the Patients and Healthy Individuals
Disease Lung cancer
Example drug Volociximab Phase 2 [521881], [1572592]
Tissue Lung tissue
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -1.17
Z-score: -2.04
P-value: 3.77E-72
Level of differential expression between the patients in the disease section of the tissue and the patients in the normal section of the tissue adjacent to the disease section Fold-change: -1.44
Z-score: -1.73
P-value: 1.73E-35
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles of the patients in the normal section of the tissue adjacent to the disease section
Target gene expression profiles in the tissue of healthy individual
Disease Melanoma
Example drug AMEP Phase 1 [551212], [1572592]
Tissue Skin
Level of differential expression between the patients in the disease section of the tissue and the tissues of healthy individual Fold-change: -0.11
Z-score: -0.11
P-value: 4.19E-01
Target gene expression profiles of the patients in the disease section of the tissue
Target gene expression profiles in the tissue of healthy individual
Target Gene Expression Profiles in Other Tissues of Healthy Individuals
Reference
Ref 551212Pre-EMP-tive strike against GBM. SciBX 7(14); doi:10.1038/scibx.2014.389. April 10 2014
Ref 521881ClinicalTrials.gov (NCT00369395) A Study of Volociximab in Metastatic Melanoma. U.S. National Institutes of Health.
Ref 1572592NCBI GEO: archive for functional genomics data sets--update.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.